Corrigendum to ‘OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer’ [Gynecol Oncol 2025 Jun 197 182–191]

Volume 203, December 2025, Pages 182-183Author links open overlay panel, , , , , , , , , , , , , , , , , , , …View Abstract

© 2025 The Author(s). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.